NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are ...

On Friday, Travere Therapeutics Inc (TVTX) stock saw a decline, ending the day at $16.41 which represents a decrease of $-0.70 or -4.09% from the prior close of $17.11. The stock opened at $17.05 and ...

Data presentations highlight the results for FILSPARI®(sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as ...

Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs.

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) and keeping the price ...

In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against the other best biotech stocks to buy under $20. The biotechnology industry is ...

Cubist Systematic Strategies LLC lessened its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by ...

Travere Therapeutics specializes in rare kidney and metabolic disease treatments with key drugs Filspari and Thiola. Filspari, a key asset for IgA Nephropathy, has received full FDA approval ...

Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

Travere Therapeutics (TVTX) shares soared 11.6% in the last trading session to close at $15.23. The move was backed by solid volume with far more shares changing hands than in a normal session.